Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

详细信息    查看全文

• 作者：Thomas Prebet ; Thorsten Braun ; Odile Beyne-Rauzy ; Francois Dreyfus ; Aspasia Stammatoullas ; Eric Wattel ; Shanti Ame ; Emmanuel Raffoux ; Jacques Delaunay ; Aude Charbonnier ; Lionel Ad猫s ; Pierre Fenaux ; Norbert Vey
• 关键词：Myelodysplasia ; Epigenetic ; Azacitidine failure ; HDAC
• 刊名：Leukemia Research
• 出版年：January, 2014
• 年：2014
• 卷：38
• 期：1
• 页码：29-33
• 全文大小：443 K

文摘

Outcome of patients with myelodysplastic syndrome after azacitidine failure is poor. In this population, we combined cytarabine (10-20 mg/m²/day 14 days) with vorinostat (400 mg/day) for escalating durations (7 days, 10 days and 14 days), and starting on day 1 (concomitant arm) or on day 14 (sequential arm) following a 3 + 3 phase I design. 40 patients were treated. Dose limiting toxicities were all seen in sequential arm. The overall response rate was 15% with 4 responses in concomitant arm (ORR = 25%). We conclude that this combination is tolerable and concomitant administration might be less toxic and have better therapeutic effect (clinicaltrials.gov ).